- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06599021
Swallowing Difficulties in People Over 60 Years: Prevalence, Degree of Difficulty and Intervention
April 22, 2026 updated by: Lisa Tuomi
Participants included in SCAPIS2 (Swedish Cardio Pulmonary bioimage study) are screened regarding swallowing difficulty using a timed water swallow test.
Participants who show signs of swallowing difficulty (dysphagia) are included in the present study, which encompasses s flexible endoscopic evaluation of swallowing function (FEES).
Participants showing a moderate-severe dysphagia are randomized into one of three intervention groups: muscle strengthening training, skill-based swallowing training and a control group who will receive compensatory treatment.
The study is expected to improve diagnostics and treatment of swallowing difficulties in an ageing population.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
99
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Gothenburg, Sweden, 43362
- Recruiting
- Sahlgrenska University Hospital
-
Contact:
- Lisa Tuomi
-
Contact:
- Lisa Tuomi, PhD
- Phone Number: +46 (0)313421000
- Email: tuomi.lisa@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Participation in SCAPIS2
- Swallowing dysfunction according to timed water swallow test or
- Swallowing dysfunction according to self-report
Exclusion Criteria:
- Severely impaired intellectual abilities.
- Inability to consent to inclusion in the study.
- Inability to answer written questionnaires in Swedish
Inclusion of non-dysphagia control cohort: No signs of aspiration, slow swallowing (<10 ml/sec) or self-rated difficulties with eating and swallowing in sub-study SCAPIS2
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Muscular strengthening training
The muscular strengthening training is permformed 3 times daily as "head-ups" where the participant lies down and lifts their head anf then holds it upright during 60 seconds.
This is repeated x 3 followed by 30 head-lifts.
The duration of the training programme is 6 weeks.
|
6 weeks daily muscular strengthening training.
|
|
Experimental: Skill-based training
During the skill-based training programme, food and beverages are used as swallowing training material based on a pre-determined food-hierarchy.
The training starts at the highest level that the participant can safely swallow and then progresses as strength and coordination of swallowing improves.
This training is comprised of 15 speech- and language pathologist lead training sessions during 3 weeks.
|
15 sessions skill based swallowing training lead by a speech and language pathologist during 3 weeks.
|
|
No Intervention: Compensatory treatment
The control group will receive information about dysphagia and advise on compensatory strategies.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Penetration-aspiration score (PAS)
Time Frame: Baseline to post-intervention (6 weeks)
|
Ranges from 1-8 where 8 indicates worst possible aspiration score.
Swallowing safety measured from Flexible Endoscopic Examination of Swallowing (FEES).
|
Baseline to post-intervention (6 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dysphagia related symtoms
Time Frame: Up to 12 months post-intervention
|
Patient reported outcome measurement (PROM) with Swallowing quality of life (Swal-QOL).
Measures QOL depending of swallowing difficulty.
Consists of 44 items divided into 10 domains and a symtom frequency scale.
Scores on each domain is transformed into scores ranging from 0-100, where 100 indicates best possible swallowing QOL.
The Swedish version has been fond valid and reliable.
|
Up to 12 months post-intervention
|
|
Tongue strength
Time Frame: Up to 12 months post-intervention
|
Anterior and posterior tongue strength during swallowing and maximal effort is measured with the Iowa Oral Performance Instrument (IOPI)
|
Up to 12 months post-intervention
|
|
Body composition
Time Frame: Up to 12 months post-intervention
|
Body composition will be measured using Bioelectric impedance analysis (BIA).
Provides measures of fat-free mass and fat.
|
Up to 12 months post-intervention
|
|
Cost of intervention
Time Frame: Up to 12 months post-intervention
|
Will be provided through hospital records regarding number of hospital visits and in-hospital treatment during 1 year from start of intervention.
|
Up to 12 months post-intervention
|
|
Self-perceived swallowing function
Time Frame: Up to 12 months post-intervention
|
Measured with the Swedish Eating assessment tool (ÄT-10).
10 items with scores ranging from 0 to 40, higher scores indicates worse function.
Scores above 3 points are considered to identify the prevalence of a swallowing dysfunction.
|
Up to 12 months post-intervention
|
|
Assessment of swallowing efficiency
Time Frame: Up to 12 months post-intervention
|
Measurement of swallowing efficiency will be performed with the validated scale such as Yale oropharyngeal residue scale where scores range between 1-5 (none-severe)
|
Up to 12 months post-intervention
|
|
Assessment of secretion
Time Frame: Up to 12 months post-intervention
|
Measurement of swallowing function will be performed with assessment of secretion using a validated eight-point scale assesses secretion severity under the subcategories of location, amount, and response.
Assessment is performed in a blinded manner.
|
Up to 12 months post-intervention
|
|
Assessment of swallowing initiation
Time Frame: Up to 12 months post-intervention
|
Initiation of swallowing will be assessed in a blinded manner, where initiation will be categorized referring to where te bolus reaches befor swallowing is initiated.
|
Up to 12 months post-intervention
|
|
Assessment of overall swallowing function from the FEES
Time Frame: Up to 12 months post-intervention
|
Measurement of swallowing function will be performed with the Swedish tool DIGEST-FEES (Dynamic Imaging Grade of Swallowing Toxicity; FEES = flexible endoscopic evaluation of swallowing).
This be utilized to describe the severity of safety, efficiency, and pharyngeal stage overall swallowing impairment on FEES.
The tool will be validated for the participant group through comparisons with the other measures of swallowing function.
The scale ranges from 0 (normal) to 4=life threatening
|
Up to 12 months post-intervention
|
|
EQ5D quality of life questionnaire
Time Frame: Up to 12 months post-intervention
|
Measured with the EQ5D 5 L. Each domain is rated on a scale from 1-5 where a higher number indicates lower QOL.
|
Up to 12 months post-intervention
|
|
RAND-36 Quality of Life questionnaire
Time Frame: Up to 12 months post-intervention
|
Measured with the RAND-36.
Scores range between 0-100, where 100 indicates best possible outcome.
|
Up to 12 months post-intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2024
Primary Completion (Estimated)
April 1, 2027
Study Completion (Estimated)
April 1, 2028
Study Registration Dates
First Submitted
September 10, 2024
First Submitted That Met QC Criteria
September 16, 2024
First Posted (Actual)
September 19, 2024
Study Record Updates
Last Update Posted (Actual)
April 27, 2026
Last Update Submitted That Met QC Criteria
April 22, 2026
Last Verified
April 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2024-00262-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.